Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line

Dong Yan1 Department of Oncology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People’s Republic of China;2 Translational Molecular pathology, M.D Anderson Cancer Center, Houston, TX, USA

Yang Ge1 Department of Oncology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People’s Republic of China

Haiteng Deng3 School of Sciences, Tsinghua University, Beijing, People’s Republic of China

Wenming Chen4 Department of Hematology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence[email protected]

Guangyu An1 Department of Oncology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence[email protected]

Pages 1603-1610 | Published online: 03 Jul 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

AshkenaziAHerbstRSTo kill a tumor cell: the potential of proapoptotic receptor agonistsJ Clin Invest20081181979199018523647
PubMed Web of Science ®Google Scholar
JinZEl-DeiryWSOverview of cell death signaling pathwaysCancer Biol Ther20054213916315725726
PubMed Web of Science ®Google Scholar
OikonomouEPintzasAThe TRAIL of oncogenes to apoptosisBiofactors201339434335423813857
PubMed Web of Science ®Google Scholar
MinakawaTToumeKAraiMAKoyanoTKowithayakornTIshibashiMPrenylflavonoids isolated from Artocarpus champeden with TRAIL-resistance overcoming activityPhytochemistry20139629930424074554
PubMed Web of Science ®Google Scholar
SoriaJCMokTSCappuzzoFJännePAEGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospectsCancer Treat Rev201238541643022119437
PubMed Web of Science ®Google Scholar
ReungwetwattanaTDyGKTargeted therapies in developent for non-small cell lung cancerJ Carcinog2013122224574860
PubMedGoogle Scholar
StegehuisJHde WiltLHde VriesEGGroenHJde JongSKruytFATRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectivesDrug Resist Updat2010131–221520036602
PubMed Web of Science ®Google Scholar
ShraderMPinoMSLashingerLGefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expressionCancer Res20076741430143517308080
PubMed Web of Science ®Google Scholar
OmarHAArafaESMaghrabiIAWengJRSensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a Novel Akt/NF-κB signalling inhibitorBasic Clin Pharmacol Toxicol2014114646447124401154
PubMed Web of Science ®Google Scholar
KimEHYoonMJKimSUKwonTKSohnSChoiKSArsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulationCancer Res200868126627518172319
PubMed Web of Science ®Google Scholar
LouYFZouZZChenPJCombination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cellsPLoS One20149e9771924874286
PubMed Web of Science ®Google Scholar
FukuokaMYanoSGiacconeGMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]J Clin Oncol200321122237224612748244
PubMed Web of Science ®Google Scholar
UliviPZoliWCapelliLChiadiniECalistriDAmadoriDTarget therapy in NSCLC patients: relevant clinical agents and tumour molecular characterizationMol Clin Oncol20131457558124649213
PubMedGoogle Scholar
PowrózekTKrawczykPRamlauREGFR gene mutations in patients with adenosquamous lung carcinomaAsia Pac J Clin Oncol201410434034524575772
PubMed Web of Science ®Google Scholar
BergeEMDoebeleRCTargeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptorSemin Oncol201441111012524565585
PubMed Web of Science ®Google Scholar
VoortmanJResendeTPAbouELHassanMAGiacconeGKruytFATRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomibMol Cancer Ther2007672103211217620439
PubMed Web of Science ®Google Scholar
LlobetDEritjaNEncinasMCK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cellsOncogene200827182513252417982483
PubMed Web of Science ®Google Scholar
GibsonSBEpidermal growth factor and trail interactions in epithelial-derived cellsVitam Horm20046720722715110179
PubMed Web of Science ®Google Scholar
GibsonEMHensonESHaneyNVillanuevaJGibsonSBEpidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c releaseCancer Res200262248849611809700
PubMed Web of Science ®Google Scholar
LiZXuXBaiLChenWLinYEpidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cellsJ Biol Chem201128624211642117221525012
PubMed Web of Science ®Google Scholar
ZangFWeiXLengXYuMSunBC-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancerBiochem Biophys Res Commun201445026727324909691
PubMed Web of Science ®Google Scholar
YuSYLiuHFWangSPChangCCTsaiCMChaoJIEvidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cellsChem Biol Interact2013203241242223523951
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date